BWP
IMUX icon

Balboa Wealth Partners’s Immunic IMUX Stock Holding History

Balboa Wealth Partners’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,200
Closed -$13.3K – 491
2026
Q1 		$13.3K Hold
1,200
– – ﹤0.01% 452
2025
Q4 		$6.4K Hold
1,200
– – ﹤0.01% 433
2025
Q3 		$10.6K Hold
1,200
– – ﹤0.01% 407
2025
Q2 		$8.37K Hold
1,200
– – ﹤0.01% 376
2025
Q1 		$13.1K Hold
1,200
– – ﹤0.01% 323
2024
Q4 		$12K Hold
1,200
– – ﹤0.01% 336
2024
Q3 		$19.8K Buy
+1,200
New +$17.1K ﹤0.01% 323
2024
Q2 		– Sell
-1,200
Closed -$15.8K – 320
2024
Q1 		$15.8K Hold
1,200
– – ﹤0.01% 290
2023
Q4 		$18K Hold
1,200
– – 0.01% 276
2023
Q3 		$17.6K Hold
1,200
– – 0.01% 272
2023
Q2 		$30.1K Buy
+1,200
New +$20.1K 0.01% 272

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balboa Wealth Partners's IMUX Position: Q2 2026 in Review

Balboa Wealth Partners sold out of Immunic (IMUX) in Q2 2026, closing a stake of 1,200 shares — an estimated $13.3K sold.

Balboa Wealth Partners first reported a position in IMUX in Q2 2023 and held it in 11 quarters. The position peaked at $30.1K in Q2 2023. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Balboa Wealth Partners reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
  • Balboa Wealth Partners sold 1,200 Immunic shares in Q2 2026, an estimated $13.3K.
  • Balboa Wealth Partners first reported a position in Immunic in Q2 2023 and held it in 11 quarters.
  • Balboa Wealth Partners's Immunic position peaked at $30.1K in Q2 2023.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Balboa Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.